多重化診断薬市場：方法、用途、エンドユーザー別-2025-2030年の世界予測

多重化診断薬市場は、2023年に149億8,000万米ドルと評価され、2024年には173億6,000万米ドルに達すると予測され、CAGR 16.62％で成長し、2030年には439億7,000万米ドルに達すると予測されています。

多重化診断薬は、1回の検査で複数のバイオマーカーや分析物を同時に検出・分析するもので、医療用途における診断精度と効率性の向上に大きな可能性を提供します。多重化診断薬の必要性は、がん、感染症、慢性疾患などの複雑な疾患の管理に不可欠な、包括的で迅速な診断ソリューションに対するニーズの高まりから生じています。これらの診断薬は、病気のスクリーニングから個別化医療に至るまで、検査室、臨床現場、研究機関で幅広く使用されています。最終用途分野は主にヘルスケアプロバイダー、学術研究、製薬、バイオテクノロジー企業などです。市場の洞察によると、多重化診断薬市場の成長は、技術の進歩、慢性疾患の有病率の上昇、費用対効果が高く効率的な診断ソリューションに対する需要の増加によって大きく影響を受けています。さらに、ゲノミクスとプロテオミクスの進歩は、人工知能と機械学習の統合とともに、有望な機会をもたらしています。企業は、使いやすいプラットフォームの開発に注力し、ナノテクノロジーやバイオインフォマティクスなどの先端技術を取り入れることで、こうした機会を捉えることができます。しかし、初期コストの高さ、複雑な規制要件、高度な診断ツールを操作するための熟練者の必要性といった課題が、市場の成長を阻んでいます。また、この分野の技術変化のペースが速いことも課題となっており、継続的な技術革新と適応が求められています。技術革新と研究の最良の分野は、より強固で汎用性の高い多重化プラットフォーム、ポイントオブケア診断薬、低資源環境で使用するための機能拡張の開発にあります。感度と特異性を高めながらコストを削減し、患者の転帰を改善するような調査に投資することで、事業の成長を促進することができます。全体として、市場力学の性質はダイナミックで競争的であり、業界で優位に立つためには戦略的パートナーシップと最先端技術への投資が重要であることが強調されています。

市場力学：急速に進化する多重化診断薬市場の主要市場インサイトを公開

多重化診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんやその他の感染症の流行
  • ゲノミクスと個別化医療に対する民間・公的資金の増加
  • 自動化装置と分析システムの需要
• 市場抑制要因
  • 多重化レベルの制限と単一検出部位間の交差感受性の可能性
• 市場機会
  • 新しい高度な多重化診断ツールのイントロダクション
  • 次世代シーケンシングソリューションの研究開発重視の高まり
• 市場の課題
  • 多重化診断機器を扱うためのトレーニングを受けたヘルスケア専門家の不足

ポーターのファイブフォース：多重化診断薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：多重化診断薬市場における外部からの影響の把握

外部マクロ環境要因は、多重化診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析多重化診断薬市場における競合情勢の把握

多重化診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス多重化診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、多重化診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨多重化診断薬市場における成功への道筋を描く

多重化診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんやその他の感染症の蔓延
    • ゲノミクスと個別化医療への官民資金の増加
    • 自動化機器および分析システムの需要
  • 抑制要因
    • 多重化レベルが限られており、単一の検出部位間で交差感度が発生する可能性がある
  • 機会
    • 新しい高度な多重診断ツールのイントロダクション
    • 次世代シーケンシングソリューションを生み出すための研究開発活動への重点化
  • 課題
    • 多重診断機器を扱う訓練を受けたヘルスケア専門家の不足
• 市場セグメンテーション分析
  • 方法：診断における高精度のため、高密度マルチプレックスアッセイの使用が増加している
  • アプリケーション：腫瘍学疾患検出のための多重化診断薬の指数関数的使用
  • エンドユーザー：病院における多重化診断薬を使用した高度でハイスループットなスクリーニングの必要性
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 多重化診断薬市場：方法別

• 高密度マルチプレックスアッセイ
• 低密度マルチプレックスアッセイ
• 中密度マルチプレックスアッセイ
• 超高密度マルチプレックスアッセイ

第7章 多重化診断薬市場：用途別

• アレルギー疾患
• 自己免疫疾患
• 心臓病学
• 感染症
• 腫瘍学

第8章 多重化診断薬市場：エンドユーザー別

• 学術調査
• 臨床調査
• 診断ラボ
• 病院
• 製薬会社

第9章 南北アメリカの多重化診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の多重化診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの多重化診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ナノピンが血液ベースの結核検査を開始、HIV/結核のマルチプレックス検査の基盤を築く
  • ChromaCodeとProtean BioDiagnosticsが戦略的提携を締結し、米国でHDPCRベースのNSCLC検査を導入
  • EDPバイオテック、ニューデイ・ダイアグノスティクスとの合併を発表
  • デルタ・ダイアグノスティクス、バイオセンシング技術に革命を起こすためにシリーズA資金調達で525万ユーロ（576万米ドル）を調達
  • ChromaCode、MedGenomeとの提携を発表、インドと中東にHDPCRベースの診断を提供
  • Aptitudeは、BARDAと最大5,400万米ドルの提携契約を締結し、ポイントオブケアおよび在宅での使用に向けた診断法の開発に着手
  • Proxim Diagnostics、bioMerieuxからの戦略的投資を発表
  • 合成生物学スタートアップD-NomeがAnkur Capital、Campus Fundから150万米ドルの資金を調達
  • ALiA BioTechのワンストップ診断プラットフォームが医療の最前線にマルチプレックス検査をもたらす
  • アジレントとアコヤ・バイオサイエンス、バイオ医薬品アプリケーション向けマルチプレックス組織アッセイ開発を推進する提携を発表
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AccuBioTech Co., Ltd.
• Agilent Technologies, Inc.
• Akoya Biosciences
• AusDiagnostics by R-Biopharm
• Baxter International Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Cardinal Health
• Chembio
• ChromaCode, Inc.
• Danaher Corporation
• Delta Diagnostics BV
• F. Hoffmann-La Roche AG
• Genabio Diagnostics Inc.
• Hologic, Inc.
• Illumina, Inc.
• Leica Biosystems
• Medtronic PLC
• Merck KGaA
• NanoPin Technologies
• Novartis AG
• PCR Biosystems
• QIAGEN N.V.
• Quansys Biosciences Inc.
• Seegene, Inc.
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.
• West Pharmaceutical Services

LIST OF FIGURES

• FIGURE 1. MULTIPLEXED DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MULTIPLEXED DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MULTIPLEXED DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY LOW DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY MID-DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY VERY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ALLERGIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 35. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 52. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 55. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 107. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 119. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 122. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 152. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Multiplexed Diagnostics Market was valued at USD 14.98 billion in 2023, expected to reach USD 17.36 billion in 2024, and is projected to grow at a CAGR of 16.62%, to USD 43.97 billion by 2030.

Multiplexed diagnostics involves the simultaneous detection and analysis of multiple biomarkers or analytes in a single test, offering vast potential in enhancing diagnostic accuracy and efficiency in medical applications. The necessity for multiplexed diagnostics arises from the evolving needs for comprehensive and rapid diagnostic solutions, which are essential in managing complex diseases such as cancer, infectious diseases, and chronic conditions. These diagnostics are employed extensively in laboratories, clinical settings, and research institutions for applications ranging from disease screening to personalized medicine. The end-use sectors primarily include healthcare providers, academic research, pharmaceuticals, and biotechnology firms. Market insights indicate that the growth of the multiplexed diagnostics market is significantly influenced by technological advancements, the rising prevalence of chronic diseases, and an increasing demand for cost-effective and efficient diagnostic solutions. Furthermore, advancements in genomics and proteomics, along with the integration of artificial intelligence and machine learning, present promising opportunities. Companies can seize these opportunities by focusing on developing user-friendly platforms and incorporating advanced technologies such as nanotechnology and bioinformatics. However, market growth is challenged by factors such as high initial costs, complex regulatory requirements, and the need for highly skilled personnel to operate sophisticated diagnostic tools. The fast-paced nature of technological change in the field also poses a challenge, requiring continuous innovation and adaptation. The best areas of innovation and research lie in the development of more robust and versatile multiplexing platforms, point-of-care diagnostics, and scaling up capabilities for use in low-resource settings. Investing in research that enhances sensitivity and specificity while reducing costs and improving patient outcomes can drive business growth. Overall, the nature of the multiplexed diagnostics market is dynamic and competitive, emphasizing the importance of strategic partnerships and investments in cutting-edge technologies to stay ahead in the industry.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiplexed Diagnostics Market

The Multiplexed Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of cancers and other infectious diseases
  • Rise in private-public funding for genomics & personalized medicine
  • Demand for automated equipment & analytical systems
• Market Restraints
  • Limited multiplexing levels and possible cross-sensitivity between single detection sites
• Market Opportunities
  • Introduction of new and advanced multiplexed diagnostic tools
  • Increasing emphasis on R&D activities to generate next-generation sequencing solutions
• Market Challenges
  • Lack of trained healthcare professionals for handling multiplexed diagnostic equipment

Porter's Five Forces: A Strategic Tool for Navigating the Multiplexed Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiplexed Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiplexed Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiplexed Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiplexed Diagnostics Market

A detailed market share analysis in the Multiplexed Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiplexed Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiplexed Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiplexed Diagnostics Market

A strategic analysis of the Multiplexed Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiplexed Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Agilent Technologies, Inc., Akoya Biosciences, AusDiagnostics by R-Biopharm, Baxter International Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Chembio, ChromaCode, Inc., Danaher Corporation, Delta Diagnostics BV, F. Hoffmann-La Roche AG, Genabio Diagnostics Inc., Hologic, Inc., Illumina, Inc., Leica Biosystems, Medtronic PLC, Merck KGaA, NanoPin Technologies, Novartis AG, PCR Biosystems, QIAGEN N.V., Quansys Biosciences Inc., Seegene, Inc., Siemens Healthineers, Thermo Fisher Scientific, Inc., and West Pharmaceutical Services.

Market Segmentation & Coverage

This research report categorizes the Multiplexed Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Method, market is studied across High Density Multiplexed Assays, Low Density Multiplexed Assays, Mid-Density Multiplexed Assays, and Very High Density Multiplexed Assays.
• Based on Application, market is studied across Allergic Diseases, Autoimmune Diseases, Cardiology, Infectious Diseases, and Oncology.
• Based on End-User, market is studied across Academic Research, Clinical Research, Diagnostic Labs, Hospitals, and Pharma Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cancers and other infectious diseases
    • 5.1.1.2. Rise in private-public funding for genomics & personalized medicine
    • 5.1.1.3. Demand for automated equipment & analytical systems
  • 5.1.2. Restraints
    • 5.1.2.1. Limited multiplexing levels and possible cross-sensitivity between single detection sites
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new and advanced multiplexed diagnostic tools
    • 5.1.3.2. Increasing emphasis on R&D activities to generate next-generation sequencing solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of trained healthcare professionals for handling multiplexed diagnostic equipment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Method: Increased use of high-density multiplexed assays owing to their high precision in diagnostics
  • 5.2.2. Application: Exponential use of multiplexed diagnostics for oncology disease detection
  • 5.2.3. End-User: Need for advanced and high-throughput screening with multiplexed diagnostics in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Multiplexed Diagnostics Market, by Method

• 6.1. Introduction
• 6.2. High Density Multiplexed Assays
• 6.3. Low Density Multiplexed Assays
• 6.4. Mid-Density Multiplexed Assays
• 6.5. Very High Density Multiplexed Assays

7. Multiplexed Diagnostics Market, by Application

• 7.1. Introduction
• 7.2. Allergic Diseases
• 7.3. Autoimmune Diseases
• 7.4. Cardiology
• 7.5. Infectious Diseases
• 7.6. Oncology

8. Multiplexed Diagnostics Market, by End-User

• 8.1. Introduction
• 8.2. Academic Research
• 8.3. Clinical Research
• 8.4. Diagnostic Labs
• 8.5. Hospitals
• 8.6. Pharma Companies

9. Americas Multiplexed Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Multiplexed Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Multiplexed Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. NanoPin Launches Blood-Based TB Test, Lays Groundwork for Multiplex HIV/TB Testing
  • 12.3.2. ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the United States
  • 12.3.3. EDP Biotech Announces Merger with New Day Diagnostics
  • 12.3.4. Delta Diagnostics raises EUR 5.25 million (USD 5.76 million) in Series A Funding to Revolutionize Biosensing Technology
  • 12.3.5. ChromaCode Announces Partnership with MedGenome to Bring HDPCR-based Diagnostics to India and the Middle East
  • 12.3.6. Aptitude Receives up to USD 54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use
  • 12.3.7. Proxim Diagnostics Announces Strategic Investment from bioMerieux
  • 12.3.8. Synthetic biology startup D-Nome raises USD 1.5 million in funding from Ankur Capital, Campus Fund
  • 12.3.9. ALiA BioTech's One-stop Diagnostic Platform Brings Multiplex Testing to the Medical Front Line
  • 12.3.10. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AccuBioTech Co., Ltd.
• 3. Agilent Technologies, Inc.
• 4. Akoya Biosciences
• 5. AusDiagnostics by R-Biopharm
• 6. Baxter International Inc.
• 7. Becton, Dickinson and Company
• 8. Bio-Rad Laboratories, Inc.
• 9. bioMerieux SA
• 10. Cardinal Health
• 11. Chembio
• 12. ChromaCode, Inc.
• 13. Danaher Corporation
• 14. Delta Diagnostics BV
• 15. F. Hoffmann-La Roche AG
• 16. Genabio Diagnostics Inc.
• 17. Hologic, Inc.
• 18. Illumina, Inc.
• 19. Leica Biosystems
• 20. Medtronic PLC
• 21. Merck KGaA
• 22. NanoPin Technologies
• 23. Novartis AG
• 24. PCR Biosystems
• 25. QIAGEN N.V.
• 26. Quansys Biosciences Inc.
• 27. Seegene, Inc.
• 28. Siemens Healthineers
• 29. Thermo Fisher Scientific, Inc.
• 30. West Pharmaceutical Services